ZD6474 in Treating Patients With Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Lung Cancer
Interventions
DRUG

vandetanib

PROCEDURE

adjuvant therapy

Trial Locations (21)

T2N 4N2

Tom Baker Cancer Centre - Calgary, Calgary

T6G 1Z2

Cross Cancer Institute at University of Alberta, Edmonton

V1Y 5L3

British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna

V3V 1Z2

Fraser/Valley Cancer Centre at British Columbia Cancer Agency, Surrey

V5Z 4E6

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver

E1C 6ZB

Moncton Hospital, Moncton

E2L 4L2

Saint John Regional Hospital, Saint John

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

K1H 8L6

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

L2R 5K3

St. Catharines General Hospital at Niagara Health System, St. Catharines

P7B 6V4

Northwestern Ontario Regional Cancer Care at Thunder Bay Regional Health Sciences Centre, Thunder Bay

M4C 3E7

Toronto East General Hospital, Toronto

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre, Toronto

M5G 1X5

Mount Sinai Hospital - Toronto, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

N8W 2X3

Windsor Regional Cancer Centre at Windsor Regional Hospital, Windsor

H2L 4M1

Hopital Notre- Dame du CHUM, Montreal

H2W 1S6

McGill Cancer Centre at McGill University, Montreal

G1V 4G5

L'Hopital Laval, Ste-Foy

S7N 4H4

Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00066313 - ZD6474 in Treating Patients With Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter